You are here: Industry Insights > NEJM

News List

Heart inflammation risk boosted slightly by vaccine, more by COVID-19 - study firstwordpharma
August 26, 2021
Findings published in the NEJM indicate that Pfizer and BioNTech's widely used COVID-19 vaccine Comirnaty marginally increases the risk of heart inflammation, although the risk is higher among those who contract SARS-CoV-2 infection, as reported in Yahoo!
Anthos Therapeutics' Novel Factor XI Inhibitor Abelacimab Significantly Outperforms Standard of Care Enoxaparin in Prospective Phase 2 Efficacy Research Published in NEJM drugs
July 23, 2021
Anthos Therapeutics, a clinical-stage biopharma company developing innovative therapies for cardiovascular and metabolic diseases, today announced final results from the Phase 2 ANT-005 study with its novel investigational anticoagulant abelacimab.
GSK picks Kevin Sim to lead business development for pharma R&D pharmatimes
July 17, 2018
GlaxoSmithKline has named Kevin Sim as senior vice president and head of worldwide business development for pharmaceuticals R&D.
GSK picks Kevin Sim to lead business development for pharma R&D pharmatimes
July 16, 2018
GlaxoSmithKline has named Kevin Sim as senior vice president and head of worldwide business development for pharmaceuticals R&D.
NEJM publishes second successful Epidiolex trial in LGS pharmatimes
May 24, 2018
In the trial - the first dose-ranging study to compare cannabidiol to placebo as add-on therapy in LGS - both doses of Epidiolex significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic
NEJM publishes venetoclax/rituximab data pharmatimes
March 23, 2018
The combination of venetoclax and rituximab developed by AbbVie and Roche/Genentech significantly improves progression-free survival (PFS) in patients with chronic lymphocytic leukemia (CLL).